Literature DB >> 18799107

Preliminary evidence that etanercept may reduce radiographic progression in juvenile idiopathic arthritis.

S Nielsen1, N Ruperto, V Gerloni, G Simonini, E Cortis, L Lepore, M G Alpigiani, F Zulian, F Corona, M Alessio, R Barcellona, R Gallizzi, F Rossi, S Magni-Manzoni, G Lombardini, G Filocamo, R Raschetti, A Martini, A Ravelli.   

Abstract

OBJECTIVE: To investigate the rate of radiographic progression, as measured with the carpo-metacarpal ratio (Poznanski score), during etanercept (ETN) therapy in children with polyarticular juvenile idiopathic arthritis (JIA).
METHODS: Patients included in the Italian ETN registry who had a standard radiograph of both hands and wrists in the posteroanterior view made at start of treatment and after 1 year were included in the study. The clinical response was assessed by means of the ACR Pediatric definition of improvement. Radiographic progression was determined by calculating the change in the Poznanski score between the baseline and the 1-year radiographs.
RESULTS: A total of 40 patients were studied. The frequency of ACR pediatric 30, 50, and 70 response at 1 year was 77%, 72%, and 50%, respectively. The median change in the Poznanski score between baseline and 1 year was + 0.3 units, meaning that, on average, patients experienced improvement in radiographic progression.
CONCLUSION: Our pilot study provides evidence that ETN is potentially capable of reducing the progression of radiographic joint damage in JIA. This finding deserves confirmation in a controlled trial.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18799107

Source DB:  PubMed          Journal:  Clin Exp Rheumatol        ISSN: 0392-856X            Impact factor:   4.473


  19 in total

Review 1.  Advances from clinical trials in juvenile idiopathic arthritis.

Authors:  Daniel J Lovell; Nicola Ruperto; Edward H Giannini; Alberto Martini
Journal:  Nat Rev Rheumatol       Date:  2013-07-09       Impact factor: 20.543

Review 2.  Advances and challenges in imaging in juvenile idiopathic arthritis.

Authors:  Silvia Magni-Manzoni; Clara Malattia; Stefano Lanni; Angelo Ravelli
Journal:  Nat Rev Rheumatol       Date:  2012-03-27       Impact factor: 20.543

Review 3.  Etanercept: a review of its use in autoimmune inflammatory diseases.

Authors:  Lesley J Scott
Journal:  Drugs       Date:  2014-08       Impact factor: 9.546

4.  Achievement of clinical remission in patients with juvenile idiopathic arthritis under a 2-10-year Etanercept exposure.

Authors:  Maria Trachana; Polyxeni Pratsidou-Gertsi; Maria Badouraki; Anna Bettina Haidich; Grigoris Pardalos
Journal:  Clin Rheumatol       Date:  2013-04-19       Impact factor: 2.980

Review 5.  Tumor necrosis factor inhibitors in the management of juvenile idiopathic arthritis: an evidence-based review.

Authors:  Susan Shenoi; Carol A Wallace
Journal:  Paediatr Drugs       Date:  2010-12-01       Impact factor: 3.022

Review 6.  Management of Children with Juvenile Idiopathic Arthritis.

Authors:  Vijay Viswanathan; Kevin J Murray
Journal:  Indian J Pediatr       Date:  2015-12-07       Impact factor: 1.967

7.  [Current therapy of polyarticular forms of juvenile idiopathic arthritis].

Authors:  A Hospach; J M Rühlmann; F Weller-Heinemann
Journal:  Z Rheumatol       Date:  2016-04       Impact factor: 1.372

8.  Current medical treatments for juvenile idiopathic arthritis.

Authors:  Nicolino Ruperto; Alberto Martini
Journal:  Front Pharmacol       Date:  2011-10-10       Impact factor: 5.810

9.  Pediatric psoriasis: an update.

Authors:  Nanette B Silverberg
Journal:  Ther Clin Risk Manag       Date:  2009-11-02       Impact factor: 2.423

10.  Challenges in the management of juvenile idiopathic arthritis with etanercept.

Authors:  Clare E Pain; Liza J McCann
Journal:  Biologics       Date:  2009-07-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.